iRhythm Holdings, Inc. Investigation - IRTC

Company: iRhythm Holdings, Inc. (NASDAQ: IRTC)

Learn more about the iRhythm Holdings, Inc. Investigation

Required Field

$1 - $1,000
$1001 - $10,000
$10,001 - $25,000
$25,001 - $50,000
$50,001 - $100,000
$100,001 - $250,000
$250,001 - $500,000
$500,000+

Full Name

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

* By checking this box, you agree to receive text messages from us, at the cell number you provided above, regarding new cases and case updates. Reply STOP to cancel. Msg frequency varies. Msg and data rates may apply. View Terms & Privacy

Please Upload related files below

Add Transactions

Purchases

1.

Common Stock
Preferred Stock
Bonds
Calls
Puts

Additional Purchases

Sales

1.

Common Stock
Preferred Stock
Bonds
Calls
Puts

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

iRhythm Holdings, Inc. Investigation Details

iRhythm Technologies, Inc. shares fell sharply on November 6, 2026, following the release of its third-quarter financial results. Although the company reportedly delivered strong adjusted profitability and raised its full-year guidance, Q3 revenue of $221.6 million came in below Wall Street consensus estimates. Investor sentiment was also weighed down by management's decision to no longer submit Zio MCT to the FDA this year and by flat Zio AT performance that fell below management's expectations for growth. Management tied both impacts to the Company's VitalConnect acquisition.

Get Started